Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -492.89% is 23% below its 5-year average of -402.26%, around the middle of its 5-year range (-968.18%–-91.22%).
As of the fiscal period ended Tuesday, June 30, 2026. 85.36% below its 12-month average of -265.91%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -492.89%.
RETURN ON EQUITY (ROE)
-492.89%
RETURN ON EQUITY (ROE) AVG TTM
-265.91%
RETURN ON EQUITY (ROE) AVG 3Y
-265.91%
RETURN ON EQUITY (ROE) AVG 5Y
-402.26%
RETURN ON EQUITY (ROE) AVG 10Y
-159.46%
RETURN ON EQUITY (ROE) AVG 15Y
-115.52%
RETURN ON EQUITY (ROE) AVG 20Y
-122.51%
CURRENT VS TTM AVG
-85.36%
CURRENT VS 3Y AVG
-85.36%
CURRENT VS 5Y AVG
-22.53%
CURRENT VS 10Y AVG
-209.10%
CURRENT VS 15Y AVG
-326.69%
CURRENT VS 20Y AVG
-302.33%
SECTOR MEDIAN · HEALTHCARE
-40.40%
median of 667 covered companies
CURRENT VS SECTOR MEDIAN
-1120.03%
vs the sector median at left
Heron Therapeutics, Inc.
Market Cap
$63.90M
Return on Equity (ROE)
-492.89%
TTM Avg
-265.91%
3Y Avg
-265.91%
5Y Avg
-402.26%
Market Cap
$63.23M
Return on Equity (ROE)
N/A
TTM Avg
140.07%
3Y Avg
68.30%
5Y Avg
45.41%
Market Cap
$64.09M
Return on Equity (ROE)
-62.81%
TTM Avg
-75.79%
3Y Avg
-56.25%
5Y Avg
-48.09%
Market Cap
$65.15M
Return on Equity (ROE)
-8.80%
TTM Avg
-13.04%
3Y Avg
-7.69%
5Y Avg
-7.21%
Market Cap
$65.02M
Return on Equity (ROE)
N/A
TTM Avg
-26.44%
3Y Avg
-559.66%
5Y Avg
-417.87%
Market Cap
$61.77M
Return on Equity (ROE)
-76.75%
TTM Avg
-53.49%
3Y Avg
-5.79%
5Y Avg
-19.88%
Market Cap
$64.65M
Return on Equity (ROE)
-136.82%
TTM Avg
-201.41%
3Y Avg
-55.55%
5Y Avg
-39.58%
Market Cap
$65.46M
Return on Equity (ROE)
-122.71%
TTM Avg
-558.46%
3Y Avg
-307.41%
5Y Avg
-314.14%
Market Cap
$60.99M
Return on Equity (ROE)
-132.16%
TTM Avg
-74.56%
3Y Avg
-71.32%
5Y Avg
22.85%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Heron Therapeutics, Inc. (HRTX) | $63.90M | -492.89% | -265.91% | -265.91% | -402.26% |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | 140.07% | 68.30% | 45.41% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $64.09M | -62.81% | -75.79% | -56.25% | -48.09% |
| InterCure Ltd. (INCR)vs › | $65.15M | -8.80% | -13.04% | -7.69% | -7.21% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.02M | N/A | -26.44% | -559.66% | -417.87% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.77M | -76.75% | -53.49% | -5.79% | -19.88% |
| RenovoRx, Inc. (RNXT)vs › | $64.65M | -136.82% | -201.41% | -55.55% | -39.58% |
| Cingulate Inc. (CING)vs › | $65.46M | -122.71% | -558.46% | -307.41% | -314.14% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.99M | -132.16% | -74.56% | -71.32% | 22.85% |
| Adicet Bio, Inc. (ACET)vs › | $60.81M | -82.38% | -68.06% | -60.95% | -49.61% |
ROE
-492.9%
ROA
-13.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -492.89% |
| 2026-03-31 | -338.63% |
| 2025-12-31 | -140.90% |
| 2025-09-30 | -91.22% |
| 2022-09-30 | -965.71% |
| 2022-03-31 | -968.18% |
| 2021-12-31 | -284.50% |
| 2021-09-30 | -192.12% |
| 2021-06-30 | -146.23% |
| 2021-03-31 | -116.35% |
| 2020-12-31 | -96.10% |
| 2020-09-30 | -80.43% |
| 2020-06-30 | -61.19% |
| 2020-03-31 | -52.90% |
| 2019-12-31 | -50.70% |
| 2019-09-30 | -68.80% |
| 2019-06-30 | -65.87% |
| 2019-03-31 | -57.14% |
| 2018-12-31 | -48.31% |
| 2018-09-30 | -47.14% |
| 2018-06-30 | -45.22% |
| 2018-03-31 | -216.28% |
| 2017-12-31 | -150.59% |
| 2017-09-30 | -456.79% |
| 2017-06-30 | -274.48% |
| 2017-03-31 | -186.01% |
| 2016-09-30 | -874.84% |
| 2016-06-30 | -225.77% |
| 2016-03-31 | -119.20% |
| 2015-12-31 | -82.63% |
| 2015-09-30 | -61.38% |
| 2015-06-30 | -52.23% |
| 2015-03-31 | -165.41% |
| 2014-12-31 | -121.10% |
| 2014-09-30 | -86.15% |
| 2014-06-30 | -64.86% |
| 2014-03-31 | -108.05% |
| 2013-12-31 | -80.18% |
| 2013-09-30 | -234.65% |
| 2013-06-30 | -148.16% |
| 2013-03-31 | -75.83% |
| 2012-12-31 | -45.06% |
| 2012-09-30 | -34.55% |
| 2012-06-30 | -161.52% |
| 2012-03-31 | -131.66% |
| 2011-12-31 | -75.00% |
| 2011-09-30 | -47.67% |
| 2011-06-30 | -35.04% |
| 2010-12-31 | -558.21% |
| 2010-09-30 | -302.77% |
| 2010-06-30 | -179.86% |
| 2010-03-31 | -114.68% |
| 2009-12-31 | -147.56% |
| 2009-03-31 | -394.85% |
| 2008-12-31 | -304.36% |
| 2008-09-30 | -238.00% |
| 2008-06-30 | -147.60% |
| 2008-03-31 | -91.54% |
| 2007-12-31 | -68.41% |
| 2007-09-30 | -48.89% |
| 2007-06-30 | -40.94% |
| 2007-03-31 | -321.73% |
| 2006-12-31 | 43.67% |
| 2006-09-30 | 47.52% |
| 2006-06-30 | 49.08% |
| 2006-03-31 | 48.17% |
| 2005-12-31 | -132.37% |
| 2005-09-30 | -90.14% |
| 2005-06-30 | -77.02% |
| 2005-03-31 | -60.87% |
| 2004-12-31 | -65.15% |
| 2004-09-30 | -51.09% |
| 2004-06-30 | -41.05% |
| 2004-03-31 | -79.96% |
| 2003-12-31 | -38.73% |
| 2003-09-30 | -25.53% |
| 2003-06-30 | -23.55% |
